Literature DB >> 12497548

Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology.

Shahid Husain1, Nina Singh.   

Abstract

Bronchiolitis obliterans (OB) or bronchiolitis obliterans syndrome (BOS) remains a major hurdle in the long-term survival of lung transplant recipients. The pathogenesis of OB or BOS remains to be fully discerned, but it is hypothesized that allogenic or nonallogenic insults result in the release of chemokines and T lymphocytes propagating the injury and ultimately recruiting fibroblasts culminating in intraluminal proliferation. Infectious agents, with or without other exogenous factors, have been proposed to have a contributory role in the development of OB or BOS. Cytomegalovirus (CMV) is an immunomodulating virus that may lead to persistent stimulation of T cells with the release of chemokines that may promote OB. Animal studies have correlated the development of OB with CMV infection. However, assessment of CMV as a risk factor for the development of OB or BOS in clinical studies has yielded conflicting results. CMV infection was noted to have a hazard ratio of 1.62 in one study, whereas CMV pneumonitis was associated with relative risk of 2.3. Additional studies did not find a higher risk for developing OB or BOS with CMV. Other viruses including respiratory syncytial virus and parainfluenza viruses can promote epithelial damage and act synergistically with chronic rejection in the development of OB. A higher (47%) incidence of BOS has been noted during the respiratory virus season. The evidence of Pneumocystis carinii pneumonia or other infectious episodes causing OB is lacking. Thus, although the role of infectious agents in the development of OB or BOS is biologically plausible, an incontrovertible association between infection and OB or BOS has not been documented. This is a US government work. There are no restrictions on its use.

Entities:  

Mesh:

Year:  2002        PMID: 12497548     DOI: 10.1053/srin.2002.36442

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  11 in total

1.  (3)He-MRI in follow-up of lung transplant recipients.

Authors:  Klaus Kurt Gast; Julia Zaporozhan; Sebastian Ley; Alexander Biedermann; Frank Knitz; Balthasar Eberle; Joerg Schmiedeskamp; Claus-Peter Heussel; Eckhard Mayer; Wolfgang Günter Schreiber; Manfred Thelen; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2003-10-16       Impact factor: 5.315

Review 2.  The role of the bacterial microbiome in lung disease.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

3.  Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation.

Authors:  Lora D Thomas; Aaron P Milstone; Regis A Vilchez; Preeti Zanwar; Janet S Butel; J Stephen Dummer
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

4.  Antifungal prophylaxis in lung transplant: A survey of United States' transplant centers.

Authors:  Kelly M Pennington; Kathleen J Yost; Patricio Escalante; Raymund R Razonable; Cassie C Kennedy
Journal:  Clin Transplant       Date:  2019-06-23       Impact factor: 2.863

Review 5.  Infections after lung transplantation.

Authors:  Mario Nosotti; Paolo Tarsia; Letizia Corinna Morlacchi
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

6.  Distal airway microbiome is associated with immunoregulatory myeloid cell responses in lung transplant recipients.

Authors:  Nirmal S Sharma; Keith M Wille; S Athira; Degui Zhi; Kenneth P Hough; Enrique Diaz-Guzman; Kui Zhang; Ranjit Kumar; Sunad Rangarajan; Peter Eipers; Yong Wang; Ritesh K Srivastava; Jose Vicente Rodriguez Dager; Mohammad Athar; Casey Morrow; Charles W Hoopes; David D Chaplin; Victor J Thannickal; Jessy S Deshane
Journal:  J Heart Lung Transplant       Date:  2017-07-15       Impact factor: 10.247

7.  Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation.

Authors:  L Fan; H L Benson; R Vittal; E A Mickler; R Presson; A Jo Fisher; O W Cummings; K M Heidler; M R Keller; W J Burlingham; D S Wilkes
Journal:  Am J Transplant       Date:  2011-04-19       Impact factor: 8.086

8.  Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.

Authors:  Deepali Kumar; Dean Erdman; Shaf Keshavjee; Teresa Peret; Raymond Tellier; Denis Hadjiliadis; Grant Johnson; Melissa Ayers; Deborah Siegal; Atul Humar
Journal:  Am J Transplant       Date:  2005-08       Impact factor: 8.086

9.  Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations.

Authors:  Robert P Dickson; John R Erb-Downward; Christine M Freeman; Natalie Walker; Brittan S Scales; James M Beck; Fernando J Martinez; Jeffrey L Curtis; Vibha N Lama; Gary B Huffnagle
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

Review 10.  Respiratory viral infections post-lung transplantation.

Authors:  Katherine M Vandervest; Martin R Zamora
Journal:  Curr Respir Care Rep       Date:  2012-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.